biktarvy
Selected indexed studies
- Biktarvy for the treatment of HIV infection: Progress and prospects. (Biochem Pharmacol, 2023) [PMID:37858869]
- Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review. (Antivir Ther, 2023) [PMID:36802921]
- Biktarvy--another INSTI-based combination for HIV. (Med Lett Drugs Ther, 2018) [PMID:30133424]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. (2023) pubmed
- Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial. (2025) pubmed
- Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. (2020) pubmed
- Bictegravir. (2018) pubmed
- Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. (2020) pubmed
- Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. (2021) pubmed
- Biktarvy for the treatment of HIV infection: Progress and prospects. (2023) pubmed
- Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review. (2023) pubmed
- Biktarvy--another INSTI-based combination for HIV. (2018) pubmed
- Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. (2023) pubmed